AZTA Azenta, Inc.
FY2025 10-K
Azenta, Inc. (AZTA) filed its fiscal year 2025 10-K annual report with the SEC on Dec 4, 2025. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model centered on life sciences sample management and genomic services technology relying on intellectual property rights
- • Increased focus on managing risks from expiring patents starting 2025 through 2044, risking increased competition
Management Discussion & Analysis
- • Revenue details and YoY change not disclosed in provided MD&A excerpt
- • Profitability or margin figures not included in provided text
Risk Factors
- • Regulatory risk from potential misuse of synthetic gene products under genetic engineering restrictions narrowing gene synthesis markets
- • Geopolitical risk from US-China trade tensions and increased sales exposure to China (39% of revenue outside North America, growing China operations)
Get deeper insights on Azenta, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.